|
1
|
Chen D, Si W, Shen J, Du C, Lou W, Bao C,
Zheng H, Pan J, Zhong G, Xu L, et al: miR-27b-3p inhibits
proliferation and potentially reverses multi-chemoresistance by
targeting CBLB/GRB2 in breast cancer cells. Cell Death Dis.
9:1882018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo J, Gong G and Zhang B: miR-539 acts as
a tumor suppressor by targeting epidermal growth factor receptor in
breast cancer. Sci Rep. 8:20732018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chu C, Liu X, Bai X, Zhao T, Wang M, Xu R,
Li M, Hu Y, Li W, Yang L, et al: MiR-519d suppresses breast cancer
tumorigenesis and metastasis via targeting MMP3. Int J Biol Sci.
14:228–236. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tartari F, Santoni M, Pistelli M and
Berardi R: Healthcare cost of HER2-positive and negative breast
tumors in the United States (2012-2035). Cancer Treat Rev.
60:12–17. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gottesman MM and Ling V: The molecular
basis of multidrug resistance in cancer: The early years of
P-glycoprotein research. FEBS Lett. 580:998–1009. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM, Fojo T and Bates SE:
Multidrug resistance in cancer: Role of ATP-dependent transporters.
Nat Rev Cancer. 2:48–58. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pilotte J, Dupont-Versteegden EE and
Vanderklish PW: Widespread regulation of miRNA biogenesis at the
Dicer step by the cold-inducible RNA-binding protein, RBM3. PLoS
One. 6:e284462011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jonsson L, Bergman J, Nodin B, Manjer J,
Pontén F, Uhlén M and Jirström K: Low RBM3 protein expression
correlates with tumour progression and poor prognosis in malignant
melanoma: An analysis of 215 cases from the Malmö Diet and Cancer
Study. J Transl Med. 9:1142011. View Article : Google Scholar
|
|
9
|
Derry JM, Kerns JA and Francke U: RBM3, a
novel human gene in Xp11.23 with a putative RNA-binding domain. Hum
Mol Genet. 4:2307–2311. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jögi A, Brennan DJ, Rydén L, Magnusson K,
Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, et
al: Nuclear expression of the RNA-binding protein RBM3 is
associated with an improved clinical outcome in breast cancer. Mod
Pathol. 22:1564–1574. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ehlén A, Brennan DJ, Nodin B, O’Connor DP,
Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J,
Brändstedt J, Uhlén M, et al: Expression of the RNA-binding protein
RBM3 is associated with a favourable prognosis and cisplatin
sensitivity in epithelial ovarian cancer. J Transl Med. 8:782010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wright CF, Oswald BW and Dellis S:
Vaccinia virus late transcription is activated in vitro by cellular
heterogeneous nuclear ribonucleoproteins. J Biol Chem.
276:40680–40686. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Burd CG and Dreyfuss G: Conserved
structures and diversity of functions of RNA-binding proteins.
Science. 265:615–621. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kita H, Carmichael J, Swartz J, Muro S,
Wyttenbach A, Matsubara K, Rubinsztein DC and Kato K: Modulation of
poly-glutamine-induced cell death by genes identified by expression
profiling. Hum Mol Genet. 11:2279–2287. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zeng Y, Wodzenski D, Gao D, Shiraishi T,
Terada N, Li Y, Vander Griend DJ, Luo J, Kong C, Getzenberg RH, et
al: Stress-response protein RBM3 attenuates the stem-like
properties of prostate cancer cells by interfering with CD44
variant splicing. Cancer Res. 73:4123–4133. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baghdoyan S, Dubreuil P, Eberlé F and
Gomez S: Capture of cytokine-responsive genes (NACA and RBM3) using
a gene trap approach. Blood. 95:3750–3757. 2000.PubMed/NCBI
|
|
17
|
Venugopal A, Subramaniam D, Balmaceda J,
Roy B, Dixon DA, Umar S, Weir SJ and Anant S: RNA binding protein
RBM3 increases β-catenin signaling to increase stem cell
characteristics in colorectal cancer cells. Mol Carcinog.
55:1503–1516. 2016. View Article : Google Scholar
|
|
18
|
Sureban SM, Ramalingam S, Natarajan G, May
R, Subramaniam D, Bishnupuri KS, Morrison AR, Dieckgraefe BK,
Brackett DJ, Postier RG, et al: Translation regulatory factor RBM3
is a proto-oncogene that prevents mitotic catastrophe. Oncogene.
27:4544–4556. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Boman K, Segersten U, Ahlgren G, Eberhard
J, Uhlén M, Jirström K and Malmström PU: Decreased expression of
RNA-binding motif protein 3 correlates with tumour progression and
poor prognosis in urothelial bladder cancer. BMC Urol. 13:172013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jonsson L, Hedner C, Gaber A, Korkocic D,
Nodin B, Uhlén M, Eberhard J and Jirström K: High expression of
RNA-binding motif protein 3 in esophageal and gastric
adenocarcinoma correlates with intestinal metaplasia-associated
tumours and independently predicts a reduced risk of recurrence and
death. Biomark Res. 2:112014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ding K, Wu Z, Wang N, Wang X, Wang Y, Qian
P, Meng G and Tan S: MiR-26a performs converse roles in
proliferation and metastasis of different gastric cancer cells via
regulating of PTEN expression. Pathol Res Pract. 213:467–475. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu Q, Yan H, Tao SQ, Wang XN, Mou L, Chen
P, Cheng XW, Wu WY and Wu ZS: XIAP 3′-untranslated region as a
ceRNA promotes FSCN1 function in inducing the progression of breast
cancer by binding endogenous miR-29a-5p. Oncotarget. 8:16784–16800.
2017.PubMed/NCBI
|
|
23
|
Ding K, Tan S, Huang X, Wang X, Li X, Fan
R, Zhu Y, Lobie PE, Wang W and Wu Z: GSE1 predicts poor survival
outcome in gastric cancer patients by SLC7A5 enhancement of tumor
growth and metastasis. J Biol Chem. 293:3949–3964. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
25
|
Zhuang R, Rao JN, Zou T, Liu L, Xiao L,
Cao S, Hansraj NZ, Gorospe M and Wang JY: miR-195 competes with HuR
to modulate stim1 mRNA stability and regulate cell migration.
Nucleic Acids Res. 41:7905–7919. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sakurai T, Kashida H, Komeda Y, Nagai T,
Hagiwara S, Watanabe T, Kitano M, Nishida N, Fujita J and Kudo M:
Stress response protein RBM3 promotes the development of
colitis-associated cancer. Inflamm Bowel Dis. 23:57–65. 2017.
View Article : Google Scholar
|
|
27
|
Karnevi E, Dror LB, Mardinoglu A, Elebro
J, Heby M, Olofsson SE, Nodin B, Eberhard J, Gallagher W, Uhlén M,
et al: Translational study reveals a two-faced role of RBM3 in
pancreatic cancer and suggests its potential value as a biomarker
for improved patient stratification. Oncotarget. 9:6188–6200.
2017.
|
|
28
|
Ye F, Jin P, Cai X, Cai P and Cai H: High
RNA-binding motif protein 3 (RBM3) expression is independently
associated with prolonged overall survival in intestinal-type
gastric cancer. Med Sci Monit. 23:6033–6041. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Olofsson SE, Nodin B, Gaber A, Eberhard J,
Uhlén M, Jirström K and Jerkeman M: Low RBM3 protein expression
correlates with clinical stage, prognostic classification and
increased risk of treatment failure in testicular non-seminomatous
germ cell cancer. PLoS One. 10:e01213002015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Robinson RC, Turbedsky K, Kaiser DA,
Marchand JB, Higgs HN, Choe S and Pollard TD: Crystal structure of
Arp2/3 complex. Science. 294:1679–1684. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Svitkina TM and Borisy GG: Arp2/3 complex
and actin depolymerizing factor/cofilin in dendritic organization
and treadmilling of actin filament array in lamellipodia. J Cell
Biol. 145:1009–1026. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Daugherty KM and Goode BL: Functional
surfaces on the p35/ARPC2 subunit of Arp2/3 complex required for
cell growth, actin nucleation, and endocytosis. J Biol Chem.
283:16950–16959. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rauhala HE, Teppo S, Niemelä S and
Kallioniemi A: Silencing of the ARP2/3 complex disturbs pancreatic
cancer cell migration. Anticancer Res. 33:45–52. 2013.
|
|
34
|
Zhang J, Liu Y, Yu CJ, Dai F, Xiong J, Li
HJ, Wu ZS, Ding R and Wang H: Role of ARPC2 in human gastric
cancer. Mediat Inflamm. 2017:54328182017. View Article : Google Scholar
|
